Vivitrol News and Research

RSS
Vivitrol is a drug that blocks the action of opiates (drugs used to treat pain). It may be used in the treatment of intravenous opiate addiction or alcohol dependence. Vivitrol is also being studied in the treatment of breast cancer. It may block the effects of the hormone estrogen, which causes some breast cancer cells to grow, or block the blood flow to tumors. It is a type of opiate antagonist. Also called naltrexone, naltrexone hydrochloride, and ReVia.
$1.5 million grant to develop opioid treatment program for jail detainees

$1.5 million grant to develop opioid treatment program for jail detainees

Study finds rapid increase in overdose deaths involving amphetamines and methamphetamines

Study finds rapid increase in overdose deaths involving amphetamines and methamphetamines

After opioid overdose, only 30 percent get medicine to treat addiction

After opioid overdose, only 30 percent get medicine to treat addiction

People in recovery worry GOP Medicaid cuts would put treatment out of reach

People in recovery worry GOP Medicaid cuts would put treatment out of reach

BMC opens new opioid urgent care center to treat patients with substance use disorders

BMC opens new opioid urgent care center to treat patients with substance use disorders

Mass. to spend $20 million to combat opioid use

Mass. to spend $20 million to combat opioid use

Alkermes reports financial results for first quarter of 2014

Alkermes reports financial results for first quarter of 2014

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes reports 38% of year-over-year revenue growth from key products

Positive results from Alkermes VIVITROL addiction study

Positive results from Alkermes VIVITROL addiction study

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Elan Drug Technologies, Alkermes merge to form new company in Ireland

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

PMAI offers new addiction treatment options for opioid dependence

PMAI offers new addiction treatment options for opioid dependence

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes' VIVITROL medication for treatment of opioid dependence